CA2289655A1 - Combinaisons antivirales contenant le nucleoside carbocyclique 1592u89 - Google Patents

Combinaisons antivirales contenant le nucleoside carbocyclique 1592u89 Download PDF

Info

Publication number
CA2289655A1
CA2289655A1 CA002289655A CA2289655A CA2289655A1 CA 2289655 A1 CA2289655 A1 CA 2289655A1 CA 002289655 A CA002289655 A CA 002289655A CA 2289655 A CA2289655 A CA 2289655A CA 2289655 A1 CA2289655 A1 CA 2289655A1
Authority
CA
Canada
Prior art keywords
combination
functional derivative
physiologically functional
amino
purin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002289655A
Other languages
English (en)
Inventor
David Walter Barry
Martha Heider St. Clair
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9709945.1A external-priority patent/GB9709945D0/en
Priority claimed from GBGB9719883.2A external-priority patent/GB9719883D0/en
Application filed by Individual filed Critical Individual
Publication of CA2289655A1 publication Critical patent/CA2289655A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des combinaisons thérapeutiques de (-)-(1S, 4R)-4-[2-amino-6- (cyclopropylamino)-9H-purin-9-yl] -2-cyclopentène-1-méthanol (1592U89) et des inhibiteurs non-nucléosidiques de transcriptase inverse présentant une activité anti-VIH. L'invention concerne également des compositions pharmaceutiques contenant lesdites combinaisons et leur utilisation dans le traitement d'infections par le VIH.
CA002289655A 1997-05-17 1998-05-14 Combinaisons antivirales contenant le nucleoside carbocyclique 1592u89 Abandoned CA2289655A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9709945.1A GB9709945D0 (en) 1997-05-17 1997-05-17 A novel salt
GB9709945.1 1997-05-17
GBGB9719883.2A GB9719883D0 (en) 1997-09-19 1997-09-19 Antiviral combinations
GB9719883.2 1997-09-19
PCT/EP1998/002836 WO1998052570A1 (fr) 1997-05-17 1998-05-14 Combinaisons antivirales contenant le nucleoside carbocyclique 1592u89

Publications (1)

Publication Number Publication Date
CA2289655A1 true CA2289655A1 (fr) 1998-11-26

Family

ID=26311543

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002289655A Abandoned CA2289655A1 (fr) 1997-05-17 1998-05-14 Combinaisons antivirales contenant le nucleoside carbocyclique 1592u89

Country Status (12)

Country Link
EP (1) EP0979082A1 (fr)
JP (1) JP2001525839A (fr)
AR (1) AR012702A1 (fr)
AU (1) AU7912398A (fr)
BR (1) BR9809127A (fr)
CA (1) CA2289655A1 (fr)
CO (1) CO4950569A1 (fr)
HR (1) HRP980264A2 (fr)
MA (1) MA26496A1 (fr)
NO (1) NO995620L (fr)
PE (1) PE74799A1 (fr)
WO (1) WO1998052570A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP990030A2 (en) * 1998-02-17 1999-10-31 Michael B. Maurin Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1332757B1 (fr) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Formulation de comprimé d' efavirenz
PE20000559A1 (es) * 1998-05-27 2000-07-05 Merck & Co Inc Formulacion de tabletas comprimidas de efavirenz
WO2013111147A1 (fr) * 2011-12-19 2013-08-01 Hetero Research Foundation Compositions à libération prolongée de névirapine
JP6391561B2 (ja) * 2013-02-27 2018-09-19 国立大学法人京都大学 がんの予防または治療用医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc

Also Published As

Publication number Publication date
MA26496A1 (fr) 2004-12-20
AU7912398A (en) 1998-12-11
HRP980264A2 (en) 1999-02-28
JP2001525839A (ja) 2001-12-11
NO995620D0 (no) 1999-11-16
WO1998052570A1 (fr) 1998-11-26
AR012702A1 (es) 2000-11-08
BR9809127A (pt) 2000-08-01
EP0979082A1 (fr) 2000-02-16
CO4950569A1 (es) 2000-09-01
PE74799A1 (es) 1999-08-13
NO995620L (no) 2000-01-14

Similar Documents

Publication Publication Date Title
US6417191B1 (en) Synergistic combinations of zidovudine, 1592U89 and 3TC
EP0938321B1 (fr) Combinaisons comprenant du vx478, de la zidovudine et du 3tc pouvant etre utilisees dans le traitement du vih
CA2289655A1 (fr) Combinaisons antivirales contenant le nucleoside carbocyclique 1592u89
AU723877B2 (en) Combinations comprising VX478, zidovudine and/or 1592U89 for use in the treatment of HIV
CA2289654A1 (fr) Combinaisons antivirales contenant le nucleoside carbocyclique 1592u89
WO2000018384A2 (fr) Combinaisons antivirales renfermant un ester isopropylique d'acide (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylique
MXPA98010386A (en) Combinations that include vx478, zidovudina and / or 1592u89 for use in the treatment of
WO2000018383A2 (fr) Combinaisons antivirales renfermant un ester isopropylique d'acide (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylique
WO2000016754A2 (fr) Combinaisons antivirales

Legal Events

Date Code Title Description
FZDE Dead